News

Repros Therapeutics (Repros) has entered into an agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross

LigoCyte Pharmaceuticals (LigoCyte) has initiated its third human clinical trial of its norovirus vaccine. The phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered,

FDA has approved ISTA Pharmaceuticals’ (ISTA) Bepreve (bepotastine besilate ophthalmic solution) 1.5% as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis in patients

Opexa Therapeutics (Opexa) has reported results from further analysis of the double-blind, placebo-controlled, 52-week phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). The

Expanded dermatology division of Valeant Pharmaceuticals North America, Coria Laboratories has provided update on Acanya Gel (clindamycin phosphate 1.2% and BPO 2.5%). The company said the gel is

MeadWestvaco (MWV) has reported the launch of Med-Easy, the company’s medication packaging. Med-Easy is scheduled to launch this September in Europe and will be available for Rx and

DOR BioPharma (DOR) has reported that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a

Roche and RiNA have agreed to transfer the Roche Applied Science RTS Protein Expression portfolio to German company, RiNA, effective September 15, 2009. Under the agreement, RiNA will

XenoPort has reported preliminary results from a phase 2 clinical trial that evaluated the safety and tolerability of arbaclofen placarbil (AP) (XP19986), when administered without titration to patients